SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008; 26: 1-16.
  • 2
    Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of placebo arm of 2 randomized phase III trials of quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009; 199: 805-814.
  • 3
    Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56: 1-24.
  • 4
    Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendation from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010; 59: 626-629.
  • 5
    FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356: 1915-1927.
  • 6
    Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of 3 randomised clinical trials. Lancet. 2007; 369: 1693-1702.
  • 7
    Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356: 1928-1943.
  • 8
    Romanowski B, de Borba PC, Naud PS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 ASO4-adjuvanted vaccine: analysis of a randomized placebo-controlled trial up to 6.4 years. Lancet. 2009; 374: 1975-1985.
  • 9
    Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 ASO4-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374: 301-314.
  • 10
    Kahn JA, Rosenthal SL, Jin Y, Huang B, Namakydoust A, Zimet GD. Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women. Obstet Gynecol. 2008; 111: 1103-1110.
  • 11
    Conroy K, Rosenthal SL, Zimet GD, et al. Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination. J Womens Health. 2009; 18: 1679-1686.
  • 12
    Chao C, Velicer C, Slezak JM, Jacobsen SJ. Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization. Am J Epidemiol. 2010; 171: 357-367.
  • 13
    Manhart LE, Burgess-Hull AJ, Fleming CB, Bailey JA, Haggerty KP, Catalano RF. HPV vaccination among a community sample of young adult women. Vaccine. 2011; 29: 5238-5244.
  • 14
    Jain N, Euler GL, Shefer A, Lu P, Yankey D, Markowitz L. Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007. Prev Med. 2009; 48: 426-431.
  • 15
    Caskey R, Lindau ST, Alexander GC. Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. J Adolesc Health. 2009; 45: 453-462.
  • 16
    Tylor LD, Harriri S, Sternberg M, Dunne EF, Markowitz LE. Human papillomavirus vaccine coverage in the United States, National Health and Nutrition Examination Survey, 2007-2008. Prev Med. 2011; 52: 398-400.
  • 17
    Price RA, Tiro JA, Saraiya M, Meissner H, Breen N. Use of human papillomavirus vaccines among young adult women in the United States: an analysis of the 2008 National Health Interview Survey. Cancer. 2011; 117: 5560-5568.
  • 18
    Centers for Disease Control and Prevention. Vaccination coverage estimates from the National Health Interview Survey: United States, 2008. NCHS Health E-Stats 2009. Available at: http://www.cdc.gov/nchs/data/hestat/vaccine_coverage/vaccine_coverage.pdf Accessed June 5, 2012.
  • 19
    Centers for Disease Control and Prevention. Adult vaccination coverage—United States, 2010. MMWR Morb Mortal Wkly Rep. 2012; 61: 66-72.
  • 20
    National Center for Health Statistics. National Health Interview Survey (NHIS), 2010. Public use data release: NHIS survey description. Available at: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2010/srvydesc.pdf Accessed June 5, 2012.
  • 21
    Dempsey A, Cohn L, Dalton V, Ruffin M. Worsening disparities in HPV vaccine utilization among 19-26 year old women. Vaccine. 2011; 29: 528-534.
  • 22
    Khan K, Curtis CR, Ekwueme DU, et al. Preventing cervical cancer: overviews of the National Breast and Cervical Cancer Early Detection Program and 2 US immunization programs. Cancer. 2008; 113: 3004-3012.
  • 23
    Laz TH, Rahman M, Berenson AB. An update on human papillomavirus vaccine uptake among 11-17 year old girls in the United States: National Health Interview Survey, 2010. Vaccine. 2012; 30: 3534-3540.
  • 24
    Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among adolescents aged 13-17 years—United States, 2008. MMWR Morb Mortal Wkly Rep. 2009; 58: 997-1001.
  • 25
    Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13 through 17 years—United States, 2010. MMWR Morb Mortal Wkly Rep. 2011; 60: 1117-2011.
  • 26
    Merck & Co. A program to help improve patient compliance: 3 is key. 2010. Available at: http://www.merckvaccines.com/vaccines/gardasil/compliance_one.html Accessed June 5, 2012.
  • 27
    Wong CA, Berkowitz Z, Dorell CG, Price RA, Lee J, Saraiya M. Human papillomavirus vaccine uptake among 9- to 17-year-old girls: National Health Interview Survey, 2008. Cancer. 2011; 117: 5612-5620.
  • 28
    Niccolai LM, Mehta NR, Hadler JL. Racial/ethnic and poverty disparities in human papillomavirus vaccination completion. Am J Pev Med. 2011; 41: 428-433.
  • 29
    Chou B, Krill LS, Horton BB, Barat CE, Trimble CL. Disparities in human papillomavirus vaccine completion among vaccine initiators. Obstet Gynecol. 2011; 118: 14-20.
  • 30
    Schluterman NH, Terplan M, Lydecker AD, Tracy JK. Human papillomavirus (HPV) vaccine uptake and completion at an urban hospital. Vaccine. 2011; 29: 3767-3772.
  • 31
    Hewitt M, Devesa SS, Breen N. Cervical cancer screening among U.S. women: analysis of the 2000 National Health Interview Survey. Prev Med. 2004; 39: 270-278.
  • 32
    Widdice LE, Bernstein DI, Leonard AC, Marsolo KA, Kahn JA. Adherence to the HPV vaccine dosing intervals and factors associated with completion of 3 doses. Pediatrics. 2011; 127: 77-84.
  • 33
    Chao C, Velicer C, Slezak JM, Jacobsen SJ. Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization. Mayo Clin Proc. 2009; 84: 864-870.
  • 34
    McDougall JA, Madeleine MM, Daling JR, Li CI. Racial and ethnic disparities in cervical cancer incidence rates in the United States, 1992-2003. Cancer Causes Control. 2007; 18: 1175-1186.
  • 35
    National Cancer Institute. SEER stat fact sheets: cancer of the cervix uteri. Available at: http://seer.cancer.gov/statfacts/html/cervix.html Accessed June 5, 2012.